Biomarkers/urine DNA Mutational Analysis DNA Neoplasm/*urine Disease Progression Humans Mutation Neoplasm Recurrence Local/*diagnosis/genetics/*urine Sensitivity and Specificity Urinary Bladder Neoplasms/*diagnosis/genetics/*urine #BladderCancer #blcsm biomarkers molecular diagnostics urinary bladder neoplasms urine analysis Amsterdam UMC location VUmc. J. Bosschieter R.D.M. Steenbergen and J.A. Nieuwenhuijzen are inventors on patent(s) related to the work.

Carcinoma in Situ/diagnosis/epidemiology/*pathology/surgery *Cystectomy Disease-Free Survival Humans Neoplasm Recurrence Local/*diagnosis/epidemiology/pathology Prognosis Survival Analysis Treatment Outcome Ureteral Neoplasms/*diagnosis/epidemiology/pathology/secondary Urinary Bladder/pathology/surgery Urinary Bladder Neoplasms/mortality/*pathology/surgery

*Cystectomy/adverse effects/methods Humans Neoplasm Staging Neoplasm Residual/pathology/surgery *Reoperation/methods/statistics & numerical data *Urinary Bladder Neoplasms/pathology/surgery Cystoscopy Meta-analysis Neoplasm recurrence Urinary bladder neoplasms

Blood Loss Surgical *Cystectomy Diet Humans Lymph Nodes/pathology *Minimally Invasive Surgical Procedures Postoperative Complications/etiology Randomized Controlled Trials as Topic Recurrence Treatment Outcome Urinary Bladder Neoplasms/*surgery Open radical cystectomy laparoscopic radical cystectomy meta-analysis minimally invasive randomized controlled trials robot-assisted radical cystectomy

Adjuvants Immunologic/*therapeutic use Administration Intravesical BCG Vaccine/*therapeutic use Carcinoma Transitional Cell/pathology/*therapy Cystoscopy Female Humans Male Multivariate Analysis Muscle Smooth/*pathology Neoplasm Invasiveness Neoplasm Recurrence Local/*epidemiology Proportional Hazards Models Sex Factors Survival Rate Urinary Bladder Neoplasms/pathology/*therapy *Urologic Surgical Procedures Bladder cancer Gender differences Local recurrence Meta-analysis Transurethral resection of bladder tumor

Aged Biomarkers Tumor/*blood Cystectomy/*adverse effects Female Humans Leukocyte Count Lymphocytes/*pathology Male Middle Aged Monocytes/*pathology Neoplasm Recurrence Local/blood/*epidemiology Postoperative Complications/blood/*epidemiology Survival Analysis Urinary Bladder Neoplasms/*blood/pathology/surgery

Cystectomy/*adverse effects Humans Lymphatic Metastasis Neoplasm Invasiveness Neoplasm Recurrence Local/etiology/*pathology Urinary Bladder Neoplasms/pathology/*surgery Vascular Neoplasms/etiology/*pathology Bladder cancer Lymph node dissection Lymphovascular invasion Meta-analysis Metastasis Radical cystectomy

Administration Intravesical Antineoplastic Agents/*pharmacology Humans Maintenance Chemotherapy/*methods Neoplasm Invasiveness Neoplasm Recurrence Local/*prevention & control Prognosis Randomized Controlled Trials as Topic Treatment Outcome *Urinary Bladder Neoplasms/drug therapy/pathology Bladder cancer Chemotherapy Intravesical Maintenance

Carcinoma Transitional Cell/epidemiology/*surgery *Cystectomy Humans Kidney Neoplasms/*epidemiology Neoplasms Second Primary/*epidemiology Ureteral Neoplasms/*epidemiology Urethral Neoplasms/*epidemiology Urinary Bladder Neoplasms/*surgery Bladder cancer Radical cystectomy Recurrence Remnant Upper urinary tract Urethra Urothelium including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg employment/affiliation grants or funding consultancies honoraria stock ownership or options expert testimony royalties or patents filed received or pending) are the following: None.

Adenocarcinoma/epidemiology/*pathology/surgery Cystectomy/*methods Digital Rectal Examination Humans Incidental Findings Male Neoplasm Recurrence Local/pathology Prognosis Prostate/pathology Prostate-Specific Antigen Prostatectomy/*methods Prostatic Neoplasms/epidemiology/*pathology/surgery Survival Rate Urinary Bladder Neoplasms/*surgery bladder neoplasms cystectomy prostatectomy prostatic neoplasms

Administration Intravesical Aged Aged 80 and over BCG Vaccine/*therapeutic use Biopsy Needle Disease-Free Survival Female Humans Immunohistochemistry Immunotherapy/*methods In Situ Hybridization Fluorescence Male Middle Aged Neoplasm Recurrence Local/mortality/*pathology Predictive Value of Tests Prognosis Risk Assessment Survival Analysis Treatment Outcome Urinary Bladder Neoplasms/mortality/pathology/*therapy Bcg Bladder cancer Immunotherapy Personalized therapy Response prediction

Epirubicin/*therapeutic use Female Humans Immunotherapy/*methods Male Mitomycin/*therapeutic use *Mycobacterium bovis Urinary Bladder Neoplasms/immunology/pathology/*therapy Bacillus Calmette–Guérin Consistency Epirubicin Gemcitabine Heterogeneity Interferon-Alpha Intravesical instillation therapies Mitomycin C Pairwise/network meta-analysis Tumor progression Tumor recurrence

Humans Neoplasm Grading Neoplasm Invasiveness Neoplasm Recurrence Local/*pathology Neoplasm Staging Neoplasm Residual *Reoperation Risk Factors Survival Rate Urinary Bladder/pathology Urinary Bladder Neoplasms/*pathology/*surgery Bladder Cancer Detrusor Muscle Progression Re-resection Recurrence Upstaging

Humans Neoplasm Recurrence Local/*diagnosis Obesity/complications/*diagnosis Risk Factors Urinary Bladder Neoplasms/*diagnosis Bladder cancer Obesity Recurrence Survival

Adenocarcinoma/*etiology Carcinoma Squamous Cell/*etiology Carcinoma Transitional Cell/*etiology Case-Control Studies Cohort Studies Female Humans Male Neoplasm Recurrence Local Recurrence Regression Analysis Retrospective Studies Urinary Bladder Neoplasms/*etiology Urinary Tract Infections/*complications Bladder carcinoma Case–control studies Chronic urinary tract infection Meta-analysis

Adjuvants Immunologic/*administration & dosage Administration Intravesical Antineoplastic Agents/therapeutic use BCG Vaccine/*administration & dosage Humans Instillation Drug Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/pathology/*therapy Bacillus Calmette-Guerin Maintenance therapy Non-muscle-invasive bladder cancer Progression Recurrence

Adjuvants Immunologic/*administration & dosage/adverse effects Administration Intravesical Antineoplastic Agents/*administration & dosage/adverse effects BCG Vaccine Carcinoma in Situ/mortality/pathology/*therapy Combined Modality Therapy/adverse effects/methods Disease Progression Drug Administration Schedule Humans Interferon-alpha/*administration & dosage/adverse effects Neoplasm Recurrence Local Randomized Controlled Trials as Topic Time Factors Urinary Bladder Neoplasms/mortality/pathology/*therapy Withholding Treatment/statistics & numerical data

Administration Intravesical Antibiotics Antineoplastic/*administration & dosage BCG Vaccine/administration & dosage Carcinoma in Situ/*drug therapy/mortality/pathology Carcinoma Transitional Cell/*drug therapy/mortality/pathology Disease Progression Electrochemotherapy/adverse effects/*methods Humans Mitomycin/*administration & dosage Neoplasm Recurrence Local Randomized Controlled Trials as Topic Time Factors Urinary Bladder Neoplasms/*drug therapy/mortality/pathology

Anemia/*complications Cystectomy/*methods Female Humans Male Preoperative Period Proportional Hazards Models Survival Analysis Treatment Outcome Urinary Bladder Neoplasms/*surgery Anemia Bladder cancer Hemoglobin Mortality Recurrence

Administration Intravesical BCG Vaccine/administration & dosage/*therapeutic use Chemotherapy Adjuvant Dose-Response Relationship Drug Drug Administration Schedule Humans Neoplasm Recurrence Local Prospective Studies Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/*drug therapy/mortality/surgery